APLS:NGS-Apellis Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 14.88

Change

0.00 (0.00)%

Market Cap

USD 0.84B

Volume

0.18M

Average Target Price

USD 27.00 (81.45%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

N/A

USD 129.92B
GILD Gilead Sciences Inc.

N/A

USD 89.49B
BIIB Biogen Inc.

N/A

USD 67.98B
CELG Celgene Corporation

N/A

USD 60.41B
SHPG Shire plc

N/A

USD 54.84B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD 49.76B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 45.33B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 26.11B
BMRN BioMarin Pharmaceutical Inc.

N/A

USD 17.39B
INCY Incyte Corporation

N/A

USD 16.69B

ETFs Containing APLS

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.81% 49% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.81% 49% F 68% D+
Trailing 12 Months  
Capital Gain -21.27% 59% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.27% 58% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.33% 45% F 34% F
Dividend Return -0.33% 45% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 97% A+ 86% B
Risk Adjusted Return -3.11% 44% F 28% F
Market Capitalization 0.84B 79% C+ 68% D+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -7.29 73% C 79% C+
Price/Book Ratio 3.65 39% F 28% F
Price / Cash Flow Ratio -2.04 69% D+ 84% B
Price/Free Cash Flow Ratio -7.83 67% D+ 79% C+
Management Effectiveness  
Return on Equity -62.15% 47% F 17% F
Return on Invested Capital -53.68% 51% F 19% F
Return on Assets -51.36% 42% F 13% F
Debt to Equity Ratio 16.25% 48% F 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector